TORONTO, April 01, 2026 (GLOBE NEWSWIRE) -- Kala Bio Inc. (NASDAQ: KALA), a clinical-stage biopharmaceutical company at the forefront of artificial intelligence and cell and gene therapy innovation, ...
・A rescue financing and loan settlement halted an impending asset seizure after Oxford’s default. ・A two-stage preferred stock deal supplies up to $6 million to stabilize operations and restructure ...
Kala Bio Inc. KALA on Monday said it has commercially launched its first enterprise AI product, delivering on a two-week timeline. CEO Avi Minkowitz said the rollout of the Bionic Intelligence ...
KALA BIO, Inc. (NASDAQ: KALA) (“Kala” or the “Company”) today announced the initial commercial deployment of the Bionic Intelligence Research Agent (BIRA), the Company's first purpose-built agentic AI ...
ARLINGTON, Mass., May 23, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of ...
ARLINGTON, Mass., Sept. 29, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative ...
Shares of Kala Pharmaceuticals surged Wednesday after the small biotechnology company announced a drug candidate for a rare eye disease. The Food and Drug Administration has accepted Kala's ...
Kala Bio announced that it is ready to ship its first commercial AI product, which is expected to transform the company’s operations and potentially the biotech industry. The product is set to launch ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results